title: Efficacy and safety of quercetin and polyvinylpyrrolidone in treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy.
abstract: The objective/background of this work was to study the efficacy and safety of quercetin and polyvinylpyrrolidone (QP) in the treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy.
  
  
  
  The study involved 124 patients aged between 20years and 70years with newly diagnosed destructive pulmonary tuberculosis. Patients were allocated to two groups. The first (control) group of patients received standard antimycobacterial and pathogenetic therapy and included 31 (25.00±3.89%) patients. The second (main) group of patients received QP therapy in addition to chemotherapy and included 93 (75.00±3.89%) patients.
  
  
  
  Intoxication symptoms in the second group were reduced following 1.33±0.15months, whereas in the first group intoxication symptoms were reduced following 2.64±0.20months, p<.001.
  
  
  
  Administration of QP combined with chemotherapy in patients with newly diagnosed destructive pulmonary tuberculosis resulted in a comparatively quick reduction of disease manifestation.
authors.affiliation: Department of Phthisiology and Pulmonology, Kharkiv National Medical University, Kharkiv, Ukraine. Electronic address: dddimad@yandex.ua.
authors.forename: Dmytro
authors.initials: D
authors.lastname: Butov
authors.affiliation: Department of Phthisiology and Pulmonology, Kharkiv National Medical University, Kharkiv, Ukraine.
authors.forename: Svetlana
authors.initials: S
authors.lastname: Zaitseva
authors.affiliation: Department of Internal Medicine N1, Kharkiv National Medical University, Kharkiv, Ukraine.
authors.forename: Tatyana
authors.initials: T
authors.lastname: Butova
authors.affiliation: Department of Phthisiology and Pulmonology, Kharkiv National Medical University, Kharkiv, Ukraine.
authors.forename: Ganna
authors.initials: G
authors.lastname: Stepanenko
authors.affiliation: Department of Phthisiology and Pulmonology, Kharkiv National Medical University, Kharkiv, Ukraine.
authors.forename: Olga
authors.initials: O
authors.lastname: Pogorelova
authors.affiliation: Department of Internal Medicine N1, Kharkiv National Medical University, Kharkiv, Ukraine.
authors.forename: Natalia
authors.initials: N
authors.lastname: Zhelezniakova
mesh_terms: D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011205:Povidone / Q000009:adverse effects* / Q000627:therapeutic use*; D011794:Quercetin / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D011794:Quercetin; D011205:Povidone
keywords: Immunotherapy; Quercetin; Quercetin and polyvinylpyrrolidone; Treatment of tuberculosis; Tuberculosis